Q1 2026 Coherus Oncology Inc Earnings Call Transcript
Key Points
- Coherus Oncology Inc (CHRS) reported a 61% increase in LOQTORZI net sales compared to Q1 2025, indicating strong demand for their PD-1 inhibitor.
- The company has successfully completed target accrual for the CATALYST-202 study in hepatocellular carcinoma, showing progress in their clinical development program.
- Coherus Oncology Inc (CHRS) has strengthened its liquidity position with a $54 million follow-on equity offering, supporting new studies and commercialization efforts.
- The company is exploring strategic partnerships, such as the collaboration with J&J on a T-cell engager combination, to expand the clinical development of Tagmokitug.
- Coherus Oncology Inc (CHRS) is focusing on reducing chemo-only use and curbing off-label PD-1 use in nasopharyngeal cancer, aiming to drive growth through targeted education and marketing efforts.
- The company experienced a decline in LOQTORZI net sales from Q4 2025 to Q1 2026, attributed to severe weather impacting patient treatment cycles.
- There is uncertainty in the CCR8 competitive field, with some market participants pausing or stopping their programs, which could affect Coherus Oncology Inc (CHRS)'s strategic objectives.
- The company faces challenges in achieving the right drug and target combination for their CCR8-based Treg depletion platform, which is crucial for their development strategy.
- Coherus Oncology Inc (CHRS) reported a decrease in R&D and SG&A expenses, reflecting tight spending discipline, but this could also indicate potential limitations in resource allocation for growth.
- The company has yet to provide full-year 2026 revenue guidance, creating uncertainty about future financial performance and market expectations.
Good day, and thank you for standing by. Welcome to the Q1 2026 Coherus Oncology Inc earnings conference call.
(Operator Instructions)
Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Carrie Graham. Please go ahead.
Thank you, Heidi. Good afternoon, and welcome to Coherus Oncology's first quarter 2026 earnings conference call.
Joining me today to discuss our results are Dennis Lanfear, Chief Executive Officer of Coherus; Dr. Rosh Dias, Chief Medical Officer; Dr. Theresa LaVallee, Chief Scientific and Development Officer; Sameer Goregaoker, Chief Commercial Officer; and Bryan McMichael, Chief Financial Officer.
Before we get started, I would like to remind you that today's call includes forward-looking statements regarding Coherus's current expectations about future events. Actual results may vary significantly, and we undertake no duty to update or
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
